 |
|
Current Immunotherapy for Demyelinating Diseases
Arch Neurol. 2002;59:726-731.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
DEMYELINATION IS the partial or total loss of the myelin sheath of nerve
fibers following normal myelin development. Multiple sclerosis (MS) is the
most common acquired inflammatory demyelinating disease of the central nervous
system. The presumed immune-mediated nature of demyelinating diseases prompted
evaluation of immunomodulatory and immunosuppressive agents for their treatment.
The management of demyelinating diseases, in particular MS, has evolved significantly
during the last decade. This has shifted the emphasis from treatment of acute
relapses and management of symptoms to pharmacotherapy aimed at altering the
natural history of the disease. Current relapse therapy, with glucocorticoids,
had its origin in the 1950s and is used to accelerate recovery with no clear
impact on the degree of improvement from acute neurologic dysfunction. For
more than 100 years, symptom management has used unapproved or off-label uses
of agents, with their expected benefit based on anecdotal reports or small
case series. These interventions, . . . [Full Text of this Article]TREATMENT OF CLINICALLY ISOLATED SYNDROMES
TREATMENT OF RR MS
TREATMENT OF SP MS
TREATMENT OF PRIMARY PROGRESSIVE MS
TREATMENT OF PROGRESSIVE RELAPSING MS
TREATMENT OF OTHER DEMYELINATING DISEASES
CONCLUSIONS
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(5):878-880.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Primary progressive multiple sclerosis: cerebrospinal fluid considerations
Freedman
Mult Scler 2004;10:S31-S35.
ABSTRACT
Primary progressive multiple sclerosis: cerebrospinal fluid considerations
Freedman
Mult Scler 2004;10:S31-S35.
ABSTRACT
|
